论文部分内容阅读
很多Ca~(2+)拮抗剂不断问世,而临床医生对其各自的药理作用和治疗效果可能不甚了解。WHO于1985年指定一个专家委员会讨论了这种药的分类,各种Ca~(2+)拮抗剂之间的主要区别是与其选择性、组织特异性和作用的持续时间有关的,从临床的观点来看,各种Ca~(2+)拮抗剂对心脏和心外组织的效应也不相同。WHO的这个委员会将这些药物进行了分类,以期使人们了解如何使用这类药物,并使这方面的实验室与临床资料便于相互参照。
Many Ca2 + antagonists continue to emerge, and clinicians may not be well aware of their respective pharmacological effects and therapeutic effects. The WHO designated an expert committee in 1985 to discuss the classification of this drug. The major differences between the various Ca2 + antagonists are related to their selectivity, tissue specificity and the duration of their effects, From the point of view, various Ca 2+ antagonists have different effects on heart and extracardiac tissue. The WHO committee classified the drugs in order to make people aware of how to use such drugs and to make the laboratory and clinical information in this area easier to cross-reference.